Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024 17:00 ET
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 07:00 ET
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Aegion Rebrands as Azuria Water Solutions, Signaling a New Era in Water Infrastructure Solutions
April 25, 2024 13:58 ET
|
Azuria Water Solutions
Aegion Corporation today announced its official rebrand to Azuria Water Solutions, the leading provider of technology-enabled products and services.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
April 09, 2024 16:00 ET
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Aegion Announces Acquisition of Toncco
March 27, 2024 11:00 ET
|
Aegion Corp
Aegion Corporation today announced the acquisition of Toncco, an underground utilities company based in Ogden, Utah.
Boehringer expands production site in Greece for new medicine
January 11, 2024 10:15 ET
|
Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
January 08, 2024 07:00 ET
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
EVerZom : Ambition thérapeutique dans les biothérapies à base d’exosomes
December 13, 2023 05:07 ET
|
Everzom
EVerZom : Ambition thérapeutique dans les biothérapies à base d’exosomes Lauréat de l’EIC Accelerator pour sa plateforme d’innovation technologique, EVerZom dévoile son pipeline propriétaire de...